Andelyn Biosciences Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has been selected by Drake Rayden Foundation to apply the AAV Curator Platform to manufacture clinical grade AAV for the Treatment of Nonketotic Hyperglycinemia (NKH), a rare, inherited metabolic genetic disorder caused by a mutation in the GLDC gene.

Andelyn will work closely with the Drake Rayden Foundation and scientists from Dr. Steven Gray’s laboratory at the University of Texas Southwestern (UTSW) to establish the manufacturing process in Andelyn’s AAV Curator Platform, a methodology that offers reliable speed and quality.

Matt Niloff, Chief Commercial Officer at Andelyn Biosciences said, “We are elated that our established and rapidly growing work on clinical and commercial gene therapy programs for the biotech industry allows us to also support family foundations seeking treatments for loved ones-often children with rare diseases. The power of gene therapy continues to offer the much-needed hope for the many patients with genetic diseases, and we are honored to play a pivotal role in delivering these therapies.”